lilly oral glp-1 orforglipron phase 3 weight loss trial Eli Lilly's orforglipron: a new

What are the potential serious side effects or warnings associated with GLP-1 medications

GLP-1 Analogues Market Segmentation By Route of Administration Outlook Subcutaneous Route Oral Route By Product Outlook Ozempic Trulicity Mounjaro Wegovy Rybelsus Saxenda Victoza Zepbound Other Products By Application Outlook Type 2 Diabetes Mellitus Obesity Others Applications By Distribution Channel Outlook Hospital Pharmacies Retail Pharmacies Online Pharmacies By Regional Outlook North America US Canada Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa Latin America Mexico Brazil Argentina Rest of Latin America GLP-1 Analogues Market Report Scope Source: Polaris Market Research Analysis FAQ's The global GLP-1 analogues market size was valued at USD 46.70 billion in 2024

Typically, you may be a candidate for GLP-1 therapy if you meet one of the following criteria: A BMI of 30 or higher, which is classified as obesity

If the goal is stronger, more predictable weight loss, a weekly injection may be the better fit

Whats happening

GLP-1 therapy helps reduce cravings and appetite, but lifestyle changeslike balanced nutrition and regular activityhelp maximize results